Evidence map›Paper›PMID 23752181›Full record

ArticleOncogene2014

EphA2 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells.

J Huang, D Xiao, G Li, J Ma, P Chen, W Yuan, F Hou, J Ge, M Zhong, Y Tang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 199 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. MOMASTAntioxidants (Basel, Switzerland) · 2024
    Article
  9. Article
  10. Review
  11. Article
  12. Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.International journal of molecular sciences · 2024
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Wnt3a is a promising target in colorectal cancer.Medical oncology (Northwood, London, England) · 2023
    Review
  18. Article
  19. Article
  20. Article

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

J HuangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
D XiaoDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
G LiCancer Research Institute, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Central South University, Changsha, Hunan, China.
J MaCancer Research Institute, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Central South University, Changsha, Hunan, China.
P ChenCancer Research Institute, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Central South University, Changsha, Hunan, China.
W YuanDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
F HouDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
J GeDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
M ZhongDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Y TangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
X XiaCenter for Genomic Medicine, The Methodist Hospital Research Institute, Weill Cornell School of Medicine, Houston, TX, USA.
Z ChenDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Central South University · CNXiangya Hospital Central South University · CNHouston Methodist · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to investigate the significance of erythropoietin-producing hepatocellular (Eph)A2 expression and the mechanism by which EphA2 is involved in the epithelial-mensenchymal transition (EMT) of gastric cancer cells. EphA2 expression levels were upregulated and positively correlated with metastasis and EMT markers in human gastric cancer specimens. Modulation of EphA2 expression levels had distinct effects on cell proliferation, cell cycle, migration, invasion and morphology in the gastric cancer cell lines SGC7901 and AGS in vitro and in vivo. Overexpression of EphA2 resulted in the upregulation of the EMT molecular markers N-cadherin and Snail, as well as the Wnt/β-catenin targets TCF4, Cyclin-D1 and c-Myc, while silencing EphA2 using short hairpin RNA had the opposite effect. Furthermore, inhibition of the Wnt/β-catenin pathway by XAV939 negated the effect of EphA2 overexpression, whereas activation of the Wnt/β-catenin pathway by LiCl impaired the effect of the EphA2 knockdown on EMT. These observations demonstrate that EphA2 upregulation is a common event in gastric cancer specimens that is closely correlated with cancer metastasis and that EphA2 promotes EMT of gastric cancer cells through activation of Wnt/β-catenin signaling.

Indexed as

Epithelial-Mesenchymal TransitionAdultAgedAnimalsAntigens, CDbeta CateninCadherinsCell Line, TumorCell MovementCell ProliferationFemaleGastric MucosaGene Expression Regulation, NeoplasticHumansLung NeoplasmsMaleAntigens, CDbeta CateninCadherinsCDH1 protein, humanCDH2 protein, humanCTNNB1 protein, humanReceptor, EphA2Snail Family Transcription FactorsTranscription Factors

Identifiers

PMID23752181
OpenAlexW2033576555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.